Evaluation of the effect of melatonin on patients with COVID-19 admitted to ICU: A double-blind randomized clinical trial

Q3 Medicine

Vacunas Pub Date : 2025-01-01 DOI:10.1016/j.vacun.2024.09.004

Mahmoud Ganjifard , Shokouh Ghafari , Adeleh Sahebnasagh , Mahboubeh Esmaeili , Ali Reza Amirabadizadeh , Azadeh Ebrahimzadeh , Parvin Askari , Razieh Avan

{"title":"Evaluation of the effect of melatonin on patients with COVID-19 admitted to ICU: A double-blind randomized clinical trial","authors":"Mahmoud Ganjifard , Shokouh Ghafari , Adeleh Sahebnasagh , Mahboubeh Esmaeili , Ali Reza Amirabadizadeh , Azadeh Ebrahimzadeh , Parvin Askari , Razieh Avan","doi":"10.1016/j.vacun.2024.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This research aims to examine the efficacy of melatonin as an adjuvant therapeutic agent for COVID-19 patients in the intensive care unit.</div></div><div><h3>Methods</h3><div>A randomized, double-blind, placebo-controlled investigation was conducted on a group of hospitalized COVID-19 patients. Individuals were allocated into 2 groups: one group received a combination of 18 mg of melatonin and standard treatment for 14 days; the other group received a placebo in addition to standard treatment. Patients were evaluated at the beginning of the study as well as the 7th and 15th days to analyze changes in clinical symptoms, P/F ratio, and inflammatory markers.</div></div><div><h3>Results</h3><div>The study included patients with an average age of 57.80±17.96 years, with an equal gender representation. The average length of hospital stay was 19.83±4.45 days. Hypertension and diabetes were commonly observed comorbidities. There were no significant differences in the demographic characteristics between the 2 groups (<em>P</em>  >.05).</div></div><div><h3>Conclusion</h3><div>Our study's findings suggested that melatonin is unlikely to significantly affect the clinical status of COVID-19 patients.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100377"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988724000967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and objectives

This research aims to examine the efficacy of melatonin as an adjuvant therapeutic agent for COVID-19 patients in the intensive care unit.

Methods

A randomized, double-blind, placebo-controlled investigation was conducted on a group of hospitalized COVID-19 patients. Individuals were allocated into 2 groups: one group received a combination of 18 mg of melatonin and standard treatment for 14 days; the other group received a placebo in addition to standard treatment. Patients were evaluated at the beginning of the study as well as the 7th and 15th days to analyze changes in clinical symptoms, P/F ratio, and inflammatory markers.

Results

The study included patients with an average age of 57.80 ± 17.96 years, with an equal gender representation. The average length of hospital stay was 19.83 ± 4.45 days. Hypertension and diabetes were commonly observed comorbidities. There were no significant differences in the demographic characteristics between the 2 groups (P > .05). Additionally, there were no significant distinctions between the 2 groups in terms of clinical symptom improvement, mortality rate, adverse effects, and various blood markers (P > .05).

Conclusion

Our study's findings suggested that melatonin is unlikely to significantly affect the clinical status of COVID-19 patients.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Vacunas Medicine-Infectious Diseases

CiteScore

3.90

自引率

0.00%

发文量

138

审稿时长

62 days

期刊介绍： Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.